HBME–1, CD15 and p53 Protein Expression in Thyroid Carcinoma and their Significance in Diagnosis

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Fig. 1.
Papillary thyroid carcinoma is widespread HBME–1–positive. LSAB immunoperoxidase with haematoxylin counterstain, ×200.
Download figure
Open in new tab
Download powerpoint
Fig. 2.
Follicular thyroid carcinoma is diffusely HBME–1–positive. LSAB immunoperoxidase with haematoxylin counterstain, ×200.
Download figure
Open in new tab
Download powerpoint
Fig. 3.
Microcarcinoma is strongly HBME–1 positive, in sharp contrast to the surrounding thyroid tissue. LSAB immunoperoxidase with haematoxylin counterstain, ×100.
Download figure
Open in new tab
Download powerpoint
Fig. 4.
An encapsulated thyroid nodule with extensive papillary architecture is focally HB–1–positive. LSAB immunoperoxidase with haematoxylin counterstain, ×200.
Download figure
Open in new tab
Download powerpoint
Fig. 5.
Papillary thyroid carcinoma is strongly CD15–positive. LSAB immunoperoxidase with haematoxylin counterstain, ×400.
Download figure
Open in new tab
Download powerpoint
Fig. 6.
Papillary thyroid carcinoma is p53–positive. LSAB immunoperoxidase with haematoxylin counterstain, ×400.

Table 1.

Results of immunohistochemical examinations in thyroid lesions

Diagnosis	No (total)	HBME–1 positive No(%)	CD15 positive No(%)	p53 positive No(%)
Papillary carcinoma	47	47(100.0)	17(36.2)	7(14.9)
Follicular carcinoma	9	9(100.0)	3(33.3)	1(11.1)
Medullary carcinoma	3	0	0	0
Squamous cell carcinoma	1	0	0	0
Undifferentiated carcinoma	1	0	0	1(100.0)
Adenoma	8	1(12.5)	1(12.5)	0
Nodular goiter with papillary hyperplasia	9	6(66.7)	0	0
Grave’s disease with papillary hyperplasia	7	0	0	0
Lymphocytic thyroiditis	3	0	1(33.3)	0